39.92
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Sanofi gains after expanding Regeneron partnership with $8 billion deal By Investing.com - Investing.com Australia
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNW2 Stock Price and Chart — HAN:SNW2 - TradingView
Sanofi (SNY) stock price, news, quote and history - Yahoo Finance Singapore
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
10 New 5-Star Stocks This Week - Morningstar
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
The Best Healthcare Stocks to Buy - Morningstar
DPT Vaccine Market Size Report 2026: Projected to Reach 5,281.80 Million USD, Growing at a CAGR of 0.49% - note
Sanofi transfers 20 medicines to Cheplapharm partnership - grafa.com
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY) - Seeking Alpha
Sanofi stock edges higher as Deutsche Bank reiterates Buy rating - AD HOC NEWS
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):